Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ivermectin Clear all
Completed Phase 3 Interventional Results available

Clinical Endpoint Study of Ivermectin 1% Cream

NCT02840461
View directory record Official record
Conditions
Moderate to Severe Papulopustular Rosacea
Interventions
Ivermectin Cream, 1%, Placebo/Vehicle cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 3, 2026, 11:45 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

Rosacea and Ivermectin

NCT04275999
View directory record Official record
Conditions
Rosacea
Interventions
ivermectin, digital interaction, GPSkin
Drug · Behavioral · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

NCT05736861
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 3, 2026, 11:45 AM EDT
Not listed Phase 4 Interventional

An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization

NCT04729140
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin Tablets, Doxycycline Tablets, Placebo
Drug
Lead sponsor
Max Health, Subsero Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Endpoint Study of Ivermectin 0.5% Lotion

NCT03301649
View directory record Official record
Conditions
Head Lice
Interventions
Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
6 Months and older
Enrollment
905 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.

NCT02806414
View directory record Official record
Conditions
Rosacea
Interventions
Ivermectin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 1 Interventional

A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.

NCT07795567
View directory record Official record
Conditions
Rosacea
Interventions
Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1%, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 3, 2026, 11:45 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Strongyloides Infection

NCT03605758
View directory record Official record
Conditions
Strongyloides Stercoralis Infection, Strongyloidiasis
Interventions
Ivermectin
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 3, 2026, 11:45 AM EDT
Withdrawn Phase 2 Interventional

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

NCT03553615
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ivermectin Pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 3, 2026, 11:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19

NCT05045937
View directory record Official record
Conditions
Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis
Interventions
Ivermectin
Drug
Lead sponsor
Patrick Robinson
Other
Eligibility
12 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ivermectin and Human Immunity

NCT03459794
View directory record Official record
Conditions
Ivermectin
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation

NCT00857948
View directory record Official record
Conditions
Pediculus Humanus Capitis (Head Lice)
Interventions
ivermectin treatment conditioner, Placebo, vehicle control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
6 Months and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%

NCT03257943
View directory record Official record
Conditions
Lice; Head Lice
Interventions
Ivermectin Lotion, 0.5%, SKLICE (ivermectin) Lotion, 0.5%, Vehicle of the Test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 3, 2026, 11:45 AM EDT
Withdrawn Phase 3 Interventional

Outpatient Use of Ivermectin in COVID-19

NCT04530474
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin Pill, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)

NCT05894538
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
93
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

NCT02509481
View directory record Official record
Conditions
Malaria, Lymphatic Filariasis
Interventions
Ivermectin, Albendazole
Drug
Lead sponsor
Colorado State University
Other
Eligibility
Not listed
Enrollment
2,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 4 Interventional Results available

Oracea Soolantra Association in Participants With Severe Rosacea

NCT03075891
View directory record Official record
Conditions
Rosacea
Interventions
Ivermectin 1% cream, Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules, Oral placebo capsules
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Fort Smith, Arkansas • Sacramento, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice

NCT03337490
View directory record Official record
Conditions
Head Lice
Interventions
Ivermectin 0.5% Topical Application Lotion, Ivermectin 0.5% Topical Application Lotion [SKLICE], Placebo 0% Lotion
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
6 Months to 18 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
6
States / cities
Dinuba, California • Miami, Florida • Plantation, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age

NCT00988533
View directory record Official record
Conditions
Head Lice
Interventions
0.5% Ivermectin Cream
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
6 Months to 3 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Bentonville, Arkansas • Dinuba, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Development of Ivermectin for Alcohol Use Disorders

NCT02046200
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ivermectin, Placebo, Alcohol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 3, 2026, 11:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

NCT05318469
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Ivermectin, Balstilmab, Pembrolizumab
Drug
Lead sponsor
Yuan Yuan
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 3, 2026, 11:45 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications

NCT04885530
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Fluvoxamine, Fluticasone, Placebo, Montelukast, Metformin
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
10,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 3, 2026, 11:45 AM EDT